Long‐term effects of Pfizer‐BioNTech COVID‐19 vaccinations on platelets
暂无分享,去创建一个
Gustavo K. Rohde | Nao Nitta | M. Herbig | Y. Yatomi | S. Miyata | Masako Nishikawa | K. Moriya | Y. Kanthi | H. Kanno | Ting-Hui Xiao | Walker Peterson | Yuqi Zhou | Yuma Ibayashi | Keisuke Goda | G. Rohde | M. Nishikawa | Y. Ibayashi | K. Goda | Ruoxi Yang | Tinghui Xiao
[1] P. Gresele,et al. Anti‐severe acute respiratory syndrome coronavirus‐2 adenoviral‐vector vaccines trigger subclinical antiplatelet autoimmunity and increase of soluble platelet activation markers , 2022, British journal of haematology.
[2] P. Simioni,et al. Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study , 2022, Thrombosis and haemostasis.
[3] S. Piconese,et al. Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID‐19 vaccine , 2022, Journal of Thrombosis and Haemostasis.
[4] Gustavo K. Rohde,et al. Massive image-based single-cell profiling reveals high levels of circulating platelet aggregates in patients with COVID-19 , 2021, Nature Communications.
[5] J. Nelson,et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.
[6] Yuquan Wei,et al. mRNA vaccine: a potential therapeutic strategy , 2021, Molecular Cancer.
[7] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[8] Matthew S. Miller,et al. Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.
[9] Cheng Lei,et al. Intelligent classification of platelet aggregates by agonist type , 2020, eLife.
[10] S. Massberg,et al. Patrolling the vascular borders: platelets in immunity to infection and cancer , 2019, Nature Reviews Immunology.
[11] Fumihito Arai,et al. Intelligent Image-Activated Cell Sorting , 2018, Cell.
[12] D. Weissman,et al. mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.